Salbutamol: Meter-dose inhaler of salbutamol performed using large-volume spacer
Placebo: Meter-dose inhaler of placebo performed using large-volume spacer
Study summary
β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Aerobic capacity (V̇O2max) greater than 120% predicted
* Body mass index (BMI) \> 18 and \< 30 kg/m2
* Ability to read and understand English
* Currently training and/or competing in endurance sports (i.e. running or cycling)
Exclusion Criteria:
* Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes).
* Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year.
* Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime.
* History or current symptoms of cardiopulmonary disease (excluding controlled asthma)
* Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle)
* Neuromuscular or musculoskeletal condition
Primary outcome measure(s)
Difference in time to exhaustion following salbutamol inhalation compared to placebo inhalation. — Up to 2 weeks Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill.
Sex differences in time to exhaustion following salbutamol inhalation — Up to 2 weeks Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill. Sexes will be compared within modality.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.